Molecular Pathophysiology of Hepatocellular Carcinoma: From Metabolic Inflammation to Therapeutic Targets

Background/Objectives: Hepatocellular carcinoma (HCC) is undergoing a profound epidemiological shift from viral etiologies toward metabolic dysfunction-associated steatohepatitis (MASH). Current targeted therapies often fail to provide effective responses due to the complex, interconnected nature of the tumor microenvironment. This review aims to explain the molecular axis linking chronic metabolic injury to carcinogenesis, focusing specifically on the oncoproteins Astrocyte elevated gene-1/metadherin (AEG-1/MTDH) and staphylococcal nuclease and tudor domain-containing 1 (SND1) as cooperating regulators of this disease network. Methods: This article represents a narrative review of the published literature and does not follow a systematic or exhaustive search protocol. A structured literature search using specific search terms was conducted across PubMed, Scopus, and Web of Science databases, with a last search date of May 2026. Results: Available preclinical data indicate that AEG-1 mediates early preneoplastic injury via dysregulation of hepatic lipid metabolism leading to lipotoxicity and survival of genetically unstable hepatocytes. As the disease progresses, AEG-1 amplifies NF-κB-driven inflammation and, as tumors emerge, recruits SND1 as a cooperating partner to form a gene-silencing complex that suppresses tumor suppressor proteins. Furthermore, AEG-1 and SND1 reprogram surrounding macrophages into an immunosuppressive state and drive tumor resistance to standard anti-angiogenic and chemotherapeutic drugs. Conclusions: The evidence reviewed supports a model in which HCC is driven by an interconnected metabolic-inflammatory-oncogenic cycle. AEG-1 functions as an upstream metabolic and inflammatory driver that cooperates with SND1 in a subset of oncogenic silencing events within this pathogenic network. Therefore, utilizing advanced nanomedicine platforms to simultaneously target these proteins represents a mechanistically rational therapeutic strategy that warrants further preclinical evaluation in advanced HCC.